Breast Cancer — Written Clinical Reasoning

SAQ 1 — HER2-positive breast cancer: neoadjuvant TCHP, KATHERINE, and cardiotoxicity (15 marks, 30 minutes)

Prompt: Outline your staging synthesis, the rationale and expected outcomes of neoadjuvant therapy, the response-adapted adjuvant strategy, the cardiac monitoring plan, and the role of germline genetic testing. Justify each decision with reference to evidence. [1]

Model Answer

Step 1 — The staging synthesis (3 marks): [1]

This woman has stage IIA (T2 N1 M0) HER2-positive invasive breast cancer — a 3 cm primary (T2) with one suspicious axillary node on ultrasound (clinical N1) and no distant metastases on staging CT (M0). The HER2-positive subtype (ER-negative, PR-negative, HER2 3+ by immunohistochemistry) is driven by ERBB2 gene amplification and was historically the most aggressive breast cancer subtype, with a high propensity for early systemic relapse and brain metastases. The introduction of trastuzumab and the dual HER2 blockade strategy has transformed outcomes, making HER2-positive disease one of the most treatable breast cancer subtypes [4].

The key decision point is that her tumour is over 2 cm and clinically node-positive, which makes her an ideal candidate for neoadjuvant systemic therapy rather than upfront surgery. [1]

Step 2 — Neoadjuvant therapy: rationale and regimen (5 marks): [1]

The standard neoadjuvant regimen for HER2-positive breast cancer over 2 cm or node-positive is docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) for 6 cycles (approximately 18 weeks). The rationale for neoadjuvant therapy in this patient is threefold: [1]

1. Downstaging: The 3 cm tumour with an involved node may be converted from mastectomy to breast-conserving surgery if it responds, and the axillary nodal burden may be reduced.
2. Assessing response: The pathologic complete response (pCR) rate with TCHP in HER2-positive disease is approximately 40 to 60 percent. Achieving pCR is a powerful prognostic marker — patients who achieve pCR have event-free survival rates approaching 90 percent at 5 years.
3. Treating micrometastatic disease earlier: Systemic therapy delivered before surgery addresses occult micrometastases while the primary tumour is still in situ, and the immune response to tumour antigens may be more effective. [1]

The dual HER2 blockade (trastuzumab plus pertuzumab) is superior to trastuzumab alone in the neoadjuvant setting. Pertuzumab binds a different epitope on the HER2 extracellular domain (domain II, the dimerisation domain) and prevents HER2-HER3 dimerisation, complementing trastuzumab (which binds domain IV). The combination nearly doubles the pCR rate compared with trastuzumab alone. The CLEOPATRA trial established the benefit of adding pertuzumab to trastuzumab and docetaxel in the metastatic setting, and this was extended to the neoadjuvant setting [4].

Step 3 — Response-adapted adjuvant strategy (the KATHERINE principle) (4 marks): [1]

After neoadjuvant TCHP and surgery, the adjuvant strategy depends on whether the patient achieves a pathologic complete response (pCR): [1]

• If pCR (no residual invasive disease in the breast or nodes): Continue trastuzumab to complete a total of 1 year of HER2-directed therapy (the remaining 9 months after surgery). The HERA trial established that 1 year of trastuzumab is the standard duration — 2 years offered no additional benefit [4].
• If residual invasive disease: Switch to ado-trastuzumab emtansine (T-DM1) for 14 cycles (approximately 10 months) to complete the year of HER2-directed therapy. The KATHERINE trial demonstrated that T-DM1 reduced the risk of recurrence of invasive breast cancer or death by approximately 50 percent at 3 years compared with continuing trastuzumab (invasive disease-free survival 88.3 percent versus 77.0 percent) [5]. This is now the standard of care for HER2-positive patients with residual disease after neoadjuvant therapy.

T-DM1 is an antibody-drug conjugate linking trastuzumab to DM1 (a maytansinoid microtubule inhibitor), delivering cytotoxic therapy selectively to HER2-expressing cells. Its principal toxicities are thrombocytopenia and hepatic enzyme elevation. [1]

Step 4 — Cardiac monitoring (2 marks): [1]

Both trastuzumab and pertuzumab can cause left ventricular dysfunction, and the anthracycline-free TCHP regimen was partly designed to avoid the additive cardiotoxicity of sequential anthracycline and trastuzumab. Nevertheless, cardiac monitoring is mandatory: [1]

• Baseline echocardiogram before starting therapy to establish the LVEF (must be above 50 percent to proceed).
• Serial echocardiography every 3 months during therapy.
• If LVEF drops by 10 percentage points or to below 50 percent: hold HER2-directed therapy, initiate ACE inhibitor and beta-blocker, recheck in 4 to 6 weeks. Trastuzumab-related cardiotoxicity is typically reversible, unlike anthracycline cardiotoxicity which is dose-dependent and largely irreversible. [1]

Step 5 — Germline genetic testing (1 mark): [1]

Although her tumour is HER2-positive (not triple-negative), she is 52 years old. Germline BRCA testing is not automatically indicated by age alone for HER2-positive disease, but the family history should be taken carefully. If there are features suggestive of hereditary risk (family history of breast or ovarian cancer, Ashkenazi Jewish ancestry, bilateral disease, male breast cancer in the family), she should be referred for genetic counselling and testing. If a BRCA mutation is found, she would be eligible for adjuvant olaparib per the OlympiA trial, provided the tumour is HER2-negative — but since her tumour is HER2-positive, olaparib is not currently indicated [7]. The testing would still be important for cascade testing of family members and ovarian cancer risk management.

Step 6 — Communication (1 mark): [1]

I would explain to this woman that her cancer type — HER2-positive — was once the most aggressive form of breast cancer but is now one of the most treatable, thanks to targeted therapies that attack the HER2 protein. I would describe the neoadjuvant approach: chemotherapy and targeted therapy first to shrink the tumour and test its sensitivity, then surgery, then further targeted therapy based on the response. I would be honest about the side effects — hair loss, fatigue, neuropathy, the small risk of heart effects — and about the uncertainty of the response. I would introduce the cancer nurse coordinator, offer psychological support, and document the shared decision-making. [1]

SAQ 2 — Triple-negative breast cancer: pembrolizumab and the BRCA question (10 marks, 20 minutes)

Prompt: A 41-year-old woman presents with a 3 cm triple-negative (ER-negative, PR-negative, HER2-negative) invasive ductal carcinoma with one suspicious axillary node. Her mother had breast cancer at 48 and her maternal aunt had ovarian cancer. Discuss the neoadjuvant therapy approach, the role of pembrolizumab (KEYNOTE-522), the genetic testing strategy, and the potential role of olaparib (OlympiA). [1]

Model Answer

Step 1 — The neoadjuvant therapy approach (3 marks): [1]

This woman has stage IIA (T2 N1 M0) triple-negative breast cancer (TNBC). Triple-negative disease lacks all three receptors (ER, PR, HER2), making endocrine therapy and trastuzumab ineffective. It is the most aggressive breast cancer subtype, with a peak recurrence risk in the first 1 to 3 years and a predilection for visceral and brain metastases. Neoadjuvant therapy is the standard for TNBC tumours over 2 cm or node-positive, because it enables response assessment, downstaging, and the integration of immunotherapy. [1]

The standard neoadjuvant regimen, based on the KEYNOTE-522 trial, is pembrolizumab (anti-PD-1) combined with platinum-taxane chemotherapy (paclitaxel plus carboplatin for 4 cycles, then doxorubicin or epirubicin plus cyclophosphamide for 4 cycles), followed by surgery and then adjuvant pembrolizumab for up to 9 cycles [6]. The KEYNOTE-522 trial demonstrated that this approach significantly improved both the pathologic complete response rate (64.8 percent versus 51.2 percent with placebo) and event-free survival (84.5 percent versus 76.8 percent at 5 years) compared with chemotherapy alone. The overall survival benefit has since been confirmed [6].

Step 2 — The role of pembrolizumab (2 marks): [1]

Pembrolizumab is a checkpoint inhibitor that blocks the PD-1 receptor on T cells, releasing the brake on anti-tumour immune responses. TNBC, particularly in BRCA1 carriers, tends to have a higher tumour mutational burden and more tumour-infiltrating lymphocytes, making it more immunogenic than other subtypes. The KEYNOTE-522 regimen is now the standard of care for high-risk early-stage TNBC (tumours over 1 cm or node-positive) [6].

The immune-related adverse effects of pembrolizumab — thyroid dysfunction (both hypo- and hyperthyroidism), colitis, pneumonitis, hepatitis, and rarely myocarditis — must be monitored for throughout treatment and for months afterward. Baseline thyroid function tests are essential. [1]

Step 3 — Genetic testing strategy (2 marks): [1]

This patient has a strong family history (mother with breast cancer at 48, aunt with ovarian cancer) and a triple-negative tumour at age 41. She meets multiple criteria for germline genetic testing: [1]

• Triple-negative breast cancer under age 60 — all such patients should be offered BRCA testing.
• Early-onset breast cancer (under 45).
• Family history of breast and ovarian cancer. [1]

She should be referred for multigene panel testing (BRCA1, BRCA2, PALB2, TP53, CHEK2, and others). The probability of finding a BRCA1 mutation is high given the triple-negative histology and family history. If she tests positive for a BRCA1 mutation, this has implications for: [1]

• Her treatment: She would be eligible for adjuvant olaparib (see below) [7].
• Her ovarian cancer risk: BRCA1 confers a 40 to 60 percent lifetime ovarian cancer risk, and risk-reducing bilateral salpingo-oophorectomy would be recommended after childbearing, around age 35 to 40.
• Her family: Cascade testing would be offered to her first-degree relatives (children when they reach adulthood, siblings, and her mother if still alive).

Step 4 — The potential role of olaparib (OlympiA) (2 marks): [1]

If she is found to carry a germline BRCA1 or BRCA2 mutation and has high-risk HER2-negative breast cancer (which her TNBC is), she would be eligible for 1 year of adjuvant olaparib after completing standard chemotherapy, based on the OlympiA trial. Olaparib is a PARP inhibitor that exploits synthetic lethality: PARP repairs single-strand DNA breaks, and inhibiting it in a cell with defective homologous recombination (due to BRCA loss) causes lethal double-strand breaks selectively in the tumour. The OlympiA trial showed that adjuvant olaparib improved 3-year invasive disease-free survival from 77.1 percent to 85.9 percent (hazard ratio 0.58) [7].

The principal toxicities of olaparib are myelosuppression (especially anaemia and neutropenia), fatigue, and nausea. It is given orally for 1 year. Importantly, olaparib is indicated for HER2-negative breast cancer — it is not used for HER2-positive disease. [1]

Step 5 — Communication (1 mark): [1]

I would explain that her cancer type — triple-negative — is aggressive but that we now have powerful new treatments, including immunotherapy, that have changed the outlook. I would explain the neoadjuvant approach, the genetic testing, and the potential for olaparib if she carries a BRCA mutation. I would be honest about the intensity of treatment and the importance of the genetic result for her and her family. I would offer fertility preservation counselling before chemotherapy, as she is 41 and the treatment will induce premature ovarian insufficiency. [1]